article thumbnail

Economics and risks of FDA’s Quality management maturity rating programme

European Pharmaceutical Review

Can continuous manufacturing add shareholder value for pharmaceutical companies? The current state of the pharmaceutical market is characterised by an asymmetric information problem that introduces several market imperfections. Supply Chains of Quality Pharmaceuticals. October 2019. April 2022.